#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Breast cancer Li-Fraumeni syndrome Neuroendocrine cell hyperplasia of infancy Stevens-Johnson syndrome Transferrin decreased Liver abscess Advanced systemic mastocytosis Prodromal Alzheimer's disease Dermatomyositis Heritable pulmonary arterial hypertension VEXAS syndrome Facioscapulohumeral muscular dystrophy Anaemia Mucous membrane pemphigoid Hyperinsulinism More trials…

    Learn about Rare Diseases

    Advanced systemic mastocytosis – Trials in Disease Short-bowel syndrome – Diagnostics Rhabdomyosarcoma Mucopolysaccharidosis I – Basic Information Adrenogenital syndrome – Basic Information Marfan’s syndrome – Treatment Usher’s syndrome – Trials in Disease Pemphigus – Basic Information Pleomorphic leiomyosarcoma Noonan syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Xanthum Gum Pegargiminase GVV858 SAT-3247 OXALATE AMG 732 Deferoxamine Mesilate Immunoglobulin G Acalabrutinib CAMOSTAT MESILATE Ursodoxicoltaurine Acetylsalicylic Acid Ph. Eur. Exagamglogene Autotemcel Balcinrenone Navtemadlin Vincristine Sulfate Tebentafusp Ferumoxytol Crizanlizumab Irbesartan Rosuvastatin Calcium More therapies…

    Learn about Your Condition

    Laryngeal cancer stage I Atrial septal defect Thymoma malignant Vesicoureteric reflux Juvenile psoriatic arthritis Pertussis Hyperthyroidism Cardiac arrest Corneal graft rejection Prostate cancer Breast cancer Coeliac disease Gestational diabetes Pleomorphic leiomyosarcoma Meningorrhagia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Skin cancer

  • Testing bifikafusp alfa, onfekafusp alfa, and pembrolizumab combination in patients with advanced melanoma that did not respond to previous immunotherapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bifikafusp Alfa
    • Onfekafusp Alfa
    • Pembrolizumab
    Germany Italy

  • Study of DYP688 for Patients with Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Uveal melanoma
    • Skin cancer
    Investigated Drugs:
    • Dyp688
    France Germany The Netherlands Spain

  • Study of L19IL2 and L19TNF for Patients with Skin Cancer Suitable for Direct Tumor Injection

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Skin cancer
    Investigated Drugs:
    • Bifikafusp Alfa
    • Onfekafusp Alfa
    France Italy Spain

  • Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Thyroid cancer
    • Transitional cell cancer of the renal pelvis and ureter
    • Malignant melanoma
    Investigated Drugs:
    • Jk08
    • Lenvatinib
    • Pembrolizumab
    Belgium Spain

  • Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Metastatic malignant melanoma
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Alectinib
    • Alectinib Hydrochloride
    • Cobimetinib
    Belgium Czechia France Germany Greece Hungary +5

  • Study of 89Zirconium-labeled ipilimumab distribution in patients with metastatic melanoma receiving ipilimumab/nivolumab combination therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Skin cancer
    Investigated Drugs:
    • Ipilimumab
    The Netherlands
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!